SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026.
Read more at globenewswire.comMyriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026
Provided By GlobeNewswire – Last update: